Tell me what do you focus more on in virtual learning? I will try to vary my backgrounds as a virtual home yours! @RheumNow @CRASCRRheum #ACR20

Nintedanib for RA-ILD? In the INBUILD Trial, pts on Nintedanib did better than PBO, efficacy similar among autoimmune ILDs including RA. @RheumNow #ACR20 @joanbathon https://t.co/I4AJlemIhD

Dr Hansen at 3S008 on "Bone for the Holidays": individualize the decision for drug holidays - here are the key questions: #acr20 @Rheumnow https://t.co/lMHtYW4OzE

Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20

In SpA-paz cohort 80% of axSpA pts achieved R or LDA at one visit, but only 40% maintained this level of disease control. #ABS0893 #ACR20 @RheumNow https://t.co/3MKBKOoNSw https://t.co/pTMJhtfKbU

• Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients …

OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX) Abstr#808 #ACR20 @rheumnow https://t.co/TDmV0EJTp8

• Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthrit…

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

Wonderful Philip Hench Memorial Lecture from Prof Gerd Bursmester on the development of biologics in rheumatology from infections, the magic bullet, serendipity, perseverance, research to the present day @RheumNow #ACR20 #3S007 https://t.co/9H1AmZLTpJ

ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s

For patients with #rheumatic disease, what test do you request in the work-up for Latent TB infection? @RheumNow #ACR20

Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis. How/when do you use IVIG for tx of DM? @RheumNow #ACR20

Great talk by @lovetolearn27 Prosthetic joint infection doubles the risk of venous thromboembolism after revision of knee replacement. 15 yr data New York state -25K revisions! @RheumNow #ACR20 ABS#0960 https://t.co/4PHHSEstKs

Never forget how far we have come in rheumatology therapeutics, in a very short period of time. Some of the original slides that Tiny Maini and Marc Feldmann used. @r_burmester giving the Phillip Hench Lecture #ACR20 @RheumNow https://t.co/YI32BX2iw8

How often, if ever, do you use DECT to diagnose gout?

Efficacy of IVIG in Dermatomyositis Treatment 1st Placebo controlled RCT 1️⃣79% responder by total improvement score vs. 44% 2️⃣Efficacy sustained thru wk 40 3️⃣6% serious AE - thromboembolic event @RheumNow #ACR20 Abs#0955 #ACRbest https://t.co/715h1UkZ9X